FindTrial
Sign In

BNT327 Dose Level 1 (DL1)

DRUG2 trials

Sponsors

BioNTech SE

Conditions

Extensive-stage Small-cell Lung CancerLocally Advanced Breast CancerMetastatic Triple Negative Breast CancersSmall-cell Lung CancerTriple Negative Breast Cancer

Phase 2

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Active, not recruitingNCT06449222
BioNTech SELocally Advanced Breast Cancer, Metastatic Triple Negative Breast Cancers, Triple Negative Breast Cancer
Start: 2024-08-26End: 2029-06-01Updated: 2026-06-30
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Active, not recruitingNCT06449209
BioNTech SEExtensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Start: 2024-08-05End: 2028-02-01Target: 110Updated: 2026-09-14

Related Papers

Abstract PS1-13-25: Preliminary data from a global multicohort Phase2 randomized trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy for 1L/2L+ locally advanced/metastatic TNBC
Clinical Cancer Research2026-02-17
The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer
Cancer Medicine2025-09-01
Abstract PS3-08: Interim Overall Survival of Patients with Locally Advanced or Metastatic Triple-Negative Breast Cancer treated with First Line PM8002/BNT327 in Combination with Nab-Paclitaxel in Phase Ib/II Study
Clinical Cancer Research2025-06-13